- Home
- MTEX vs APRE Comparison
MTEX vs APRE Comparison
Compare MTEX & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTEX
- APRE
- Stock Information
- Founded
- MTEX 1993
- APRE 2006
- Country
- MTEX United States
- APRE United States
- Employees
- MTEX N/A
- APRE N/A
- Industry
- MTEX Medicinal Chemicals and Botanical Products
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MTEX Health Care
- APRE Health Care
- Exchange
- MTEX Nasdaq
- APRE Nasdaq
- Market Cap
- MTEX 21.2M
- APRE 21.2M
- IPO Year
- MTEX 1999
- APRE 2019
- Fundamental
- Price
- MTEX $11.24
- APRE $2.62
- Analyst Decision
- MTEX
- APRE Strong Buy
- Analyst Count
- MTEX 0
- APRE 2
- Target Price
- MTEX N/A
- APRE $15.50
- AVG Volume (30 Days)
- MTEX 6.5K
- APRE 35.9K
- Earning Date
- MTEX 03-27-2025
- APRE 03-25-2025
- Dividend Yield
- MTEX N/A
- APRE N/A
- EPS Growth
- MTEX N/A
- APRE N/A
- EPS
- MTEX N/A
- APRE N/A
- Revenue
- MTEX $121,552,000.00
- APRE $1,310,839.00
- Revenue This Year
- MTEX N/A
- APRE $134.21
- Revenue Next Year
- MTEX N/A
- APRE N/A
- P/E Ratio
- MTEX N/A
- APRE N/A
- Revenue Growth
- MTEX N/A
- APRE 130.31
- 52 Week Low
- MTEX $6.75
- APRE $2.15
- 52 Week High
- MTEX $16.49
- APRE $8.85
- Technical
- Relative Strength Index (RSI)
- MTEX 46.46
- APRE 30.05
- Support Level
- MTEX $10.50
- APRE $2.59
- Resistance Level
- MTEX $11.95
- APRE $3.72
- Average True Range (ATR)
- MTEX 0.66
- APRE 0.35
- MACD
- MTEX 0.00
- APRE -0.13
- Stochastic Oscillator
- MTEX 26.91
- APRE 1.41
About MTEX Mannatech Incorporated
Mannatech Inc is a wellness solution provider. The company develops and sells nutritional supplements, topical and skin care and anti-aging products, and weight-management products that target optimal health and wellness. Mannatech sells products in three regions: the Americas (the United States, Canada, and Mexico); Europe/the Middle East/Africa (EMEA) (Austria, the Czech Republic, Denmark, Estonia, Finland, Germany, the Republic of Ireland, Namibia, the Netherlands, Norway, South Africa, Spain, Sweden, and the United Kingdom); and Asia/Pacific (Australia, Japan, New Zealand, the Republic of Korea, Singapore, Taiwan, Hong Kong, and China). Mannatech generates the majority of its revenue from the Americas.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.